XCancer

IL-2 PET Imaging in Advanced Solid Tumours

Description:

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer \[18F\]AlF-RESCA-IL2 in patients prior to and during treatment.

Sponsor:

University Medical Center Groningen

Phase:

N/A

Government Study Link:

NCT05471271 - Click here to see study on

ClinicalTrials.gov

RESCA-IL2

Isotope(s):
Target(s):
  • Activated T-Cells
Ligand Class: Small Proteins and Antibody Fragments
Chelator: RESCA
Inclusion
  • At least 1 lesion that is accessible per investigator's assessment and eligible for biopsy according to standard clinical care procedures.
  • Patients with histologically confirmed diagnosis of locally advanced or metastatic solid cancer, eligible for ICI therapy as part of routine care.
  • Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions except for lesions that have progressed after radiotherapy.
Exclusion
  • Concurrent use of systemic corticosteroids \> 10 mg daily prednisone equivalent.